Trinity Capital Commits $30 Million to Iantrek for Ophthalmic Surgery Expansion
Trinity Capital has committed $30 million in a debt facility to Iantrek to accelerate commercialization of its AlloFlo Uveo platform and advance development of its BIOS pipeline. The funding follows Iantrek’s 2025 Series C and will support scaling manufacturing, distribution and regulatory activities for new ophthalmic surgery technologies.
1. Capital Commitment
Trinity Capital has committed $30 million to Iantrek in a structured debt facility, marking its latest investment in the bio-interventional ophthalmic surgery sector focused on minimally invasive glaucoma treatments like AlloFlo Uveo.
2. Use of Funds
Funding will support Iantrek’s commercial expansion efforts, including scaling production, extending distribution networks, advancing regulatory approvals for its product pipeline and increasing physician adoption of its BIOS platform.
3. Strategic Impact
The deal follows Iantrek’s 2025 Series C round and strengthens Trinity Capital’s life sciences lending vertical, offering potential for diversified returns through interest income and fees as Iantrek progresses clinical milestones.